This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: September 20, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing.

This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.

Condition Intervention Phase
Electrophysiology Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 2008
Study Start Date: January 2008
Estimated Study Completion Date: January 2010

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Diagnosis of CNV secondary to AMD
  • No other ocular disease
  • No history of kerato-refractive surgery
  • No epilepsy
  • Ability to perform electrophysiologic study

Exclusion Criteria:

  • Pregnancy
  • Minority
  • Epilepsy
  • History of kerato-refractive surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00533689

Contact: Michaella Goldstein, MD +972-3-6925773
Contact: Shiri Soudry, MD +972-3-6925773

Departent of Ophthalmlogy, Tel Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Michaella Goldstein, MD Tel-Aviv Sourasky Medical Center
Study Director: Anat Loewenstein, MD Tel-Aviv Sourasky Medical Center
Study Chair: Ido Perlman, PhD Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
  More Information Identifier: NCT00533689     History of Changes
Other Study ID Numbers: TASMC-07-MG-209-CTIL
Study First Received: September 20, 2007
Last Updated: September 20, 2007 processed this record on September 21, 2017